Related Experiment Video
Updated: May 19, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
[Systemic therapy for metastatic renal cell carcinoma]
M W Kramer1, S Steffens, C von Klot
1Klinik für Urologie und Urologische Onkologie Medizinische Hochschule Hannover, Germany.
Aktuelle Urologie
|August 8, 2012
Summary
Targeted therapies, including tyrosine kinase (TK) and mTOR inhibitors, have replaced cytokine-based treatments for advanced renal cell carcinoma. This review covers current first- and second-line systemic therapies and sequential treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Advances in understanding renal cell carcinoma (RCC) pathogenesis and prognosis.
- Shift from cytokine-based therapies to targeted agents for metastatic RCC.
Purpose of the Study:
- To review the current state of systemic therapy for renal cell carcinoma.
- To discuss first- and second-line treatment options.
- To explore sequential therapy and side effect management.
Main Methods:
- Literature review of recent advancements in RCC systemic therapy.
- Analysis of targeted therapeutic agents, including tyrosine kinase (TK) and mTOR inhibitors.
- Discussion of clinical trial data and treatment guidelines.
Main Results:
- Targeted therapies (TK and mTOR inhibitors) are now standard for advanced RCC.
- Established efficacy of specific agents in first- and second-line settings.
- Growing importance of sequential treatment strategies to optimize outcomes.
Conclusions:
- Systemic therapy for advanced renal cell carcinoma has been revolutionized by targeted agents.
- Optimal sequencing of therapies is crucial for maximizing patient benefit.
- Consideration of side effect profiles is essential for effective treatment plans.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...